Alzheimer's, the hopes of the first tests on a drug

BAN2401, which is part of these potential Alzheimer's disease drugs that attack the depots amyloid beta (drugs that have not yet yielded the desired results), was tested in a Phase II trial at different doses and only at the highest dose (tested only in 161 patients). showed tangible results on the slowing down of cognitive decline, which may require a new phase 3 trial to switch to the licensing request to the competent bodies (Food and Drug Administration).

BAN2401 has been shown to effectively remove beta-amyloid plaques in patients' brains, which in 81% of cases went from "amyloid-positive" to "amyloid-negative" (lack of plaques in the substance) . And most importantly, BAN2401 has slowed down cognitive decline, says Jim Hendrix of the Alzheimer's Association, arguing that a new trial would be needed to define the optimal dose of the drug and see if the results achieved so far can be reproduced.